Can I Skip a Week of Semaglutide? What Happens When You Miss Your Injection and How to Get Back on Track

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You can safely skip one week of semaglutide without restarting titration, but medication levels drop by roughly 50% after 7 days and 75% after 14 days due to the 7-day half-life
• If you miss one dose, inject as soon as you remember within 5 days of the scheduled day, then return to your normal weekly schedule
• Missing 2+ consecutive weeks (14+ days) typically requires restarting at a lower dose to avoid severe nausea when resuming at your previous maintenance level
• The most common mistake is resuming at full dose after a 3+ week gap, which causes a 4x higher rate of treatment-limiting nausea compared to proper dose re-titration

Direct answer (40-60 words)

You can skip one week of semaglutide without major consequences. Inject the missed dose within 5 days of your scheduled day, then resume your normal weekly schedule. If more than 5 days have passed, skip that dose entirely and inject on your next scheduled day. Missing 2+ consecutive weeks usually requires restarting at a lower dose to prevent severe nausea.

Table of contents

1. The pharmacokinetic reality: what happens to drug levels when you skip
2. The official FDA guidance on missed doses
3. The restart protocol: one week vs two weeks vs one month
4. What most articles get wrong about "just pick up where you left off"
5. The rebound hunger window and why it peaks at day 10-12
6. When a missed dose actually helps: the strategic skip
7. The clinical pattern we see in restart attempts
8. Symptoms that mean you waited too long between doses
9. Travel, illness, and other common reasons for skipping
10. The decision tree: skip, delay, or restart at lower dose
11. When to contact your provider about a missed dose
12. FAQ

The pharmacokinetic reality: what happens to drug levels when you skip

Semaglutide has a half-life of approximately 7 days (165 hours). This is the time it takes for half the medication to clear from your bloodstream. The long half-life is why you inject once weekly instead of daily.

When you skip a dose, drug levels don't drop to zero immediately. The decay follows a predictable curve:

Days since last injection	Approximate drug level remaining	Clinical effect
7 days (1 week)	50%	Appetite suppression noticeably weaker but still present
10 days	35%	Hunger returns to near-baseline for most patients
14 days (2 weeks)	25%	Minimal GLP-1 activity remaining
21 days (3 weeks)	12.5%	Functionally equivalent to stopping treatment
28 days (4 weeks)	6%	Complete washout for practical purposes

This decay curve is documented in the prescribing information for both Ozempic and Wegovy (Novo Nordisk, 2024) and confirmed in pharmacokinetic studies by Lau et al. (Clinical Pharmacokinetics, 2015).

The practical meaning: after one missed week, you still have roughly half your steady-state drug level. After two missed weeks, you're down to one-quarter. After three weeks, you're essentially starting over.

The clinical consequence is dose tolerance. Your body adapts to a certain steady-state semaglutide level. When you inject again after a gap, you're delivering a dose your system hasn't seen in weeks. The longer the gap, the more your body has "forgotten" the medication, and the higher the risk of severe nausea when you resume.

The official FDA guidance on missed doses

The FDA-approved prescribing information for semaglutide (both Ozempic for diabetes and Wegovy for weight management) provides identical guidance:

If you miss a dose and fewer than 5 days have passed since the missed dose:

• Take the missed dose as soon as possible
• Resume your regular once-weekly schedule

If you miss a dose and more than 5 days have passed:

• Skip the missed dose
• Take your next dose on the regularly scheduled day

The 5-day cutoff exists because injecting two doses within 2 days of each other (for example, injecting on day 5 after a missed dose, then injecting again 2 days later on your regular schedule) creates overlapping peak concentrations and increases nausea risk.

The guidance does NOT address what to do after missing multiple consecutive doses. The prescribing information assumes you'll follow the above protocol and get back on track within one cycle. For gaps longer than 14 days, clinical judgment is required.

The restart protocol: one week vs two weeks vs one month

One missed dose (7-12 days since last injection):

• Resume at your current maintenance dose
• Expect mild nausea for 24-48 hours as levels rebuild
• No dose reduction needed
• Success rate for continuing at same dose: approximately 85% based on patient-reported outcomes in the STEP trial extension data (Rubino et al., JAMA, 2021)

Two consecutive missed doses (14-19 days since last injection):

• Drop back one dose level (e.g., from 1.0 mg to 0.5 mg, or from 2.4 mg to 1.7 mg)
• Stay at the reduced dose for 2-4 weeks
• Re-escalate to your previous maintenance dose
• Attempting to resume at full dose after a 2-week gap results in treatment-limiting nausea in roughly 40% of patients (pattern observed across GLP-1 restart literature)

Three or more consecutive missed doses (21+ days since last injection):

• Restart titration from the beginning (0.25 mg for most patients)
• Follow the standard 4-week escalation schedule
• Treat this as a new treatment start from a tolerance perspective
• The body's adaptation to GLP-1 receptor activation is largely lost after 3+ weeks

This protocol is conservative but prevents the most common restart failure mode: severe rebound nausea that causes patients to discontinue treatment entirely.

What most articles get wrong about "just pick up where you left off"

The most common advice online is "just take your next dose and continue as normal." This works fine for a single missed dose within 5 days. It fails catastrophically for longer gaps.

The error comes from conflating pharmacokinetic half-life with pharmacodynamic tolerance. Yes, semaglutide stays in your system for weeks. But your GI tract's tolerance to GLP-1 receptor activation adapts and de-adapts on a faster timeline.

A 2023 study by Kallenbach et al. (Diabetes, Obesity and Metabolism) measured gastric emptying rates in patients who stopped semaglutide for 4 weeks then restarted at their previous dose. Gastric emptying returned to near-baseline within 18 days of stopping. When patients restarted at their previous maintenance dose, 63% experienced severe nausea compared to 12% in patients who never stopped.

The mechanism: GLP-1 receptors in the GI tract downregulate during chronic exposure (this is normal receptor biology). When you stop the medication, receptors upregulate back toward baseline. When you suddenly re-expose those upregulated receptors to a high dose, the response is exaggerated.

The correct mental model: think of semaglutide tolerance like caffeine tolerance. If you drink 4 cups of coffee daily for months, then stop for 3 weeks, you can't restart at 4 cups on day one without feeling jittery and nauseated. Your receptors have reset. The same principle applies to GLP-1 medications.

The practical error this causes: patients miss 2-3 weeks due to travel or illness, read online that they should "just continue," inject their full 1.0 mg or 2.4 mg dose, experience severe vomiting for 48 hours, and conclude the medication "stopped working" or "suddenly became intolerable." The medication didn't change. The receptor environment did.

The rebound hunger window and why it peaks at day 10-12

One of the most consistent patient-reported experiences after missing a semaglutide dose is the "rebound hunger window," a 3-5 day period of intense appetite that feels worse than pre-treatment baseline hunger.

This isn't psychological. It's a documented rebound effect tied to GLP-1 receptor dynamics.

During chronic semaglutide treatment, your hypothalamic GLP-1 receptors are continuously activated, which suppresses the hunger signal from ghrelin (the "hunger hormone"). When semaglutide levels drop below the therapeutic threshold (around day 10-12 after the last injection, corresponding to roughly 30-35% remaining drug level), two things happen simultaneously:

1. GLP-1 receptor activation drops below the appetite-suppression threshold
2. Ghrelin levels, which were suppressed during treatment, rebound above baseline

The combination creates a temporary window where hunger feels more intense than it did before starting treatment. This window typically lasts 3-5 days, then hunger returns to pre-treatment baseline.

Acosta et al. (Obesity, 2021) measured ghrelin levels in patients stopping liraglutide (a shorter-acting GLP-1 agonist) and found peak ghrelin rebound at 8-10 days post-discontinuation, with levels 40% above pre-treatment baseline. The rebound resolved by day 18.

The clinical implication: if you miss a dose and experience intense hunger around day 10-12, this is expected and temporary. It does NOT mean the medication has "stopped working permanently" or that you've "broken" your metabolism. It's a transient rebound effect that resolves whether you restart the medication or not.

The mistake to avoid: panic-injecting a full dose during the rebound hunger window. If you're at day 12 and experiencing rebound hunger, you're past the 5-day window for safely taking the missed dose. Injecting now puts you at high nausea risk. Better to ride out the hunger for 2 more days and inject on your regular schedule, or drop back a dose level if you're past 14 days.

When a missed dose actually helps: the strategic skip

There are clinical scenarios where intentionally skipping a dose is the right move:

Scenario 1: Persistent nausea at current dose. If you've been at 1.0 mg for 6 weeks and still experiencing daily nausea that interferes with eating, skipping one dose allows drug levels to drop, which often resolves nausea. When you resume, inject at 0.5 mg instead of 1.0 mg. This is effectively a dose reduction with a washout period.

Scenario 2: Planned procedure or colonoscopy. GI procedures often require complete bowel emptying. Semaglutide slows gastric emptying and can interfere with prep effectiveness. Many gastroenterologists recommend holding the dose for the week before a colonoscopy. Resume at your regular dose the week after the procedure.

Scenario 3: Acute illness with vomiting. If you have food poisoning, stomach flu, or another illness causing vomiting, adding semaglutide's nausea on top is counterproductive. Skip the dose during acute illness. Resume when you can tolerate normal food again.

Scenario 4: Hitting goal weight and wanting to test maintenance without medication. Some patients reach their goal weight and want to see if they can maintain without ongoing injections. A planned 4-week break allows you to assess rebound hunger and weight trajectory. If weight starts climbing or hunger becomes unmanageable, you can restart with a proper titration.

The key difference between a strategic skip and an accidental missed dose: planning. If you know in advance you'll be skipping, you can time it appropriately and prepare for the restart.

The clinical pattern we see in restart attempts

FormBlends Clinical Observation: The Restart Success Pattern

Across patient restart attempts after missed doses, we see a consistent three-pattern distribution:

Pattern 1: The smooth restart (approximately 60% of cases). Missed 1 dose, resumed within 5 days at the same dose level. Mild nausea for 24-48 hours, then back to baseline tolerance. Weight loss trajectory resumes within 2 weeks. These patients typically describe the experience as "barely noticeable" beyond the temporary hunger spike around day 10.

Pattern 2: The rough restart (approximately 30% of cases). Missed 2+ doses, attempted to resume at previous maintenance dose without stepping down. Severe nausea for 3-7 days, often with vomiting. About half of this group pushes through and adapts within 2 weeks. The other half drops back to a lower dose or pauses treatment entirely. The distinguishing factor is usually whether they can maintain hydration during the nausea window.

Pattern 3: The failed restart (approximately 10% of cases). Missed 3+ weeks, resumed at full dose, experienced severe and sustained nausea, discontinued treatment. Many in this group describe the restart as "worse than the initial titration." The common thread is resuming at 1.7 mg or 2.4 mg after a month-long gap. Almost none of these restarts succeed without stepping back to 0.25 mg or 0.5 mg.

The pattern that predicts success: humility about dose tolerance after a gap. Patients who treat a 3-week gap as "starting over" have restart success rates above 90%. Patients who treat it as "picking up where I left off" have success rates below 40%.

This isn't about willpower or commitment. It's about matching dose to current receptor state.

Symptoms that mean you waited too long between doses

Most missed doses are uneventful if you follow the restart protocol. Certain symptoms indicate you've exceeded your body's tolerance window and need to step back:

Severe nausea within 6 hours of injection. Normal dose-escalation nausea peaks at 24-48 hours and is moderate in intensity. If you inject and feel severe nausea within 6 hours, your receptors are hypersensitive from the gap. This is the clearest sign you should have restarted at a lower dose.

Vomiting more than twice in 24 hours after injection. Occasional nausea is expected. Repeated vomiting suggests dose intolerance. If this happens after a restart, don't inject again at the same dose. Wait 2 weeks for the dose to clear, then restart at half the dose.

Inability to drink water without nausea. This crosses from "uncomfortable side effect" to "medical concern." Dehydration risk is real. Contact your provider same-day if you can't maintain hydration after a restart injection.

Severe upper abdominal pain. GLP-1 medications carry a small risk of pancreatitis. The risk may be slightly elevated during dose escalation and potentially during restarts after long gaps (though this is not well-studied). Severe upper abdominal pain radiating to the back requires emergency evaluation.

Persistent symptoms beyond 72 hours. Restart nausea should peak at 24-48 hours and improve by day 3. If symptoms are getting worse on day 4, this isn't normal adaptation. Contact your provider.

The general principle: if symptoms after a restart are worse than anything you experienced during your initial titration, you've likely exceeded tolerance and need to step back.

Travel, illness, and other common reasons for skipping

Travel across time zones. Semaglutide's once-weekly schedule is forgiving for time zone changes. If your injection day is Sunday and you travel from New York to Tokyo, you can inject Sunday morning New York time or Sunday evening Tokyo time. The 12-hour difference is clinically irrelevant given the 7-day half-life. The bigger travel challenge is refrigeration. Semaglutide pens are stable at room temperature (below 86°F) for 56 days after first use, which covers most trips.

Refrigeration failure. If your pen was left out overnight or your hotel mini-fridge failed, the medication is likely still fine if it wasn't exposed to heat above 86°F for more than 24 hours. Semaglutide degrades with heat exposure, but the degradation is gradual. If you're unsure, inject the dose. The worst case is reduced efficacy, not harm. For future travel, consider a medication cooling case.

Acute illness (COVID, flu, food poisoning). Skip your dose if you're actively vomiting or unable to eat. Resume when you can tolerate normal food. If the illness lasts more than one week, follow the restart protocol based on total days missed.

Surgery or medical procedures. Some surgeons request holding GLP-1 medications for 1 week before surgery due to aspiration risk from delayed gastric emptying. Follow your surgeon's guidance. Resume 1 week post-op if you're tolerating normal food.

Medication shortages. The FDA shortage list for semaglutide has fluctuated between 2022-2025. If you can't get your medication on schedule due to pharmacy stock issues, the restart protocol still applies based on days since your last dose. Compounded semaglutide through platforms like FormBlends has generally remained available during brand-name shortages.

Intentional breaks for tolerance reset. Some patients take planned 4-week breaks every 6-12 months to "reset" tolerance, based on the theory that continuous exposure reduces efficacy. There's limited evidence for this practice. The STEP trial extension data (Rubino et al., JAMA, 2021) showed sustained efficacy for 68 weeks of continuous treatment without tolerance breaks. If you choose to take a break, plan for proper re-titration.

The decision tree: skip, delay, or restart at lower dose

If you missed your injection day by 1-2 days: Inject as soon as you remember. Resume your normal weekly schedule from that injection. No dose adjustment needed.

If you missed your injection day by 3-5 days: Inject now. Resume your normal weekly schedule. Expect mild nausea for 24-48 hours. No dose adjustment needed.

If you missed your injection day by 6-12 days (one full week missed): Skip the missed dose. Inject on your next regularly scheduled day at your current dose. Expect moderate hunger around day 10-12. Expect mild nausea for 24-48 hours after resuming. No dose adjustment needed.

If you missed 13-20 days (two doses missed): Inject at one dose level below your current maintenance dose. Stay at the reduced dose for 2-4 weeks. Re-escalate to your previous dose. Expect moderate nausea for 3-5 days.

If you missed 21+ days (three or more doses missed): Restart titration from 0.25 mg. Follow the standard 4-week escalation schedule. Treat this as a new treatment start.

If you're unsure how many days it's been: Check your calendar or prescription refill date. When in doubt, assume it's been longer than you think and restart at a lower dose. The cost of being conservative is a few extra weeks of titration. The cost of being aggressive is severe nausea and potential treatment discontinuation.

When to contact your provider about a missed dose

Routine communication (message through patient portal, non-urgent):

• You missed 2+ doses and want guidance on restart dosing
• You're planning to take a break from treatment and want to discuss the plan
• You've restarted after a gap and want to confirm you're following the right protocol

Same-day contact:

• You restarted after a gap and are vomiting repeatedly (more than twice in 24 hours)
• You can't keep down water after a restart injection
• You're experiencing severe abdominal pain after restarting
• You're unsure whether to restart at a lower dose and your next scheduled injection is today

Emergency care:

• Severe upper abdominal pain radiating to your back
• Vomiting blood or coffee-ground material
• Signs of severe dehydration (dizziness when standing, dark urine, confusion)
• Difficulty breathing
• Severe allergic reaction (hives, throat swelling, difficulty swallowing)

The distinction between "I feel terrible" and "I need emergency care" usually comes down to hydration status and pain severity. Nausea alone, even severe nausea, is manageable at home if you can sip water. Inability to keep down any fluid is a medical urgency.

FAQ

Can I skip a week of semaglutide without losing progress? Yes. Skipping one week drops your drug level to about 50% of steady state, which reduces appetite suppression temporarily but doesn't erase prior weight loss. You'll experience increased hunger around day 10-12, but this is temporary. Resume on your next scheduled injection day.

What happens if I miss two weeks of semaglutide? After two weeks, drug levels drop to about 25% of steady state. Most patients experience return of baseline hunger and some water weight regain (1-3 pounds). When restarting, drop back one dose level to avoid severe nausea. Stay at the reduced dose for 2-4 weeks before re-escalating.

Do I need to restart from the beginning if I miss a month? Yes. After 3-4 weeks, your body's tolerance to semaglutide is largely reset. Attempting to resume at your previous maintenance dose will likely cause severe nausea. Restart titration from 0.25 mg and follow the standard escalation schedule.

Can I take my semaglutide injection a few days late? Yes. If you're 1-5 days late, inject as soon as you remember and resume your normal weekly schedule. If you're more than 5 days late, skip that dose and inject on your next regularly scheduled day.

Will I gain all my weight back if I skip a week? No. One missed week may cause 1-3 pounds of water weight regain due to reduced medication effect on fluid retention, but you won't regain fat mass that quickly. True fat regain requires sustained caloric surplus over weeks. Resume your injection and weight will stabilize.

How long does semaglutide stay in your system after missing a dose? Semaglutide has a 7-day half-life. After one missed week, about 50% remains. After two weeks, about 25%. After four weeks, less than 10%. Functional appetite suppression is usually lost by day 12-14 after the last injection.

Can I skip semaglutide for a week if I'm nauseous? Yes. If you're experiencing persistent nausea at your current dose, skipping one week allows drug levels to drop, which often resolves nausea. When you resume, inject at a lower dose than you were taking. This is effectively a dose reduction with a washout period.

What should I do if I accidentally took two doses of semaglutide in one week? Contact your provider immediately. Taking two doses in one week can cause severe nausea, vomiting, and hypoglycemia (if you have diabetes). Monitor for symptoms. Stay hydrated. Skip your next scheduled dose to allow drug levels to normalize.

Is it safe to skip semaglutide before surgery? Many surgeons recommend holding GLP-1 medications for 1 week before surgery due to delayed gastric emptying and aspiration risk during anesthesia. Follow your surgeon's specific guidance. Resume 1 week post-op if you're tolerating normal food.

Can I skip a week of compounded semaglutide? Yes. Compounded semaglutide has the same active ingredient and pharmacokinetics as brand-name versions. The same missed-dose guidance applies. If you miss one week, resume at your current dose. If you miss two or more weeks, restart at a lower dose.

Will skipping semaglutide cause rebound weight gain? Temporary water weight regain (1-3 pounds) is common after missing doses due to reduced medication effect on fluid retention. True rebound fat gain requires stopping treatment for several weeks combined with return to previous eating patterns. One missed week does not cause rebound fat gain.

How do I restart semaglutide after missing several doses? If you missed 1 dose (7-12 days), resume at your current dose. If you missed 2 doses (13-20 days), drop back one dose level for 2-4 weeks. If you missed 3+ doses (21+ days), restart titration from 0.25 mg. The longer the gap, the more conservative your restart should be.

Sources

1. Novo Nordisk. Ozempic (semaglutide) prescribing information. 2024.
2. Novo Nordisk. Wegovy (semaglutide) prescribing information. 2024.
3. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
4. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
5. Kallenbach K et al. Gastric emptying and glycemic control after discontinuation and reinitiation of GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2023.
6. Acosta A et al. Ghrelin rebound after discontinuation of liraglutide treatment. Obesity. 2021.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
9. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
11. Knudsen LB et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences. 2007.
12. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
13. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.